Side Effects of alpha-Blocker Use: Retrograde Ejaculation
Affiliations
- PMID: 20126607
- PMCID: PMC2812888
Item in Clipboard
Side Effects of alpha-Blocker Use: Retrograde Ejaculation
Rev Urol.
2009 Fall.
Abstract
There are currently 5 alpha-blockers that are approved by the US Food and Drug Administration to treat lower urinary tract symptoms (LUTS). The American Urological Association guidelines committee believes that all alpha-blockers are equally effective. However, alpha-blockers differ in their likelihood of causing abnormal ejaculation. This article discusses the effects on ejaculatory function, and specifically retrograde ejaculation, of the currently available alpha-blockers being used to treat men with LUTS due to benign prostatic hyperplasia.
Keywords: Benign prostatic hyperplasia; Lower urinary tract symptoms; Retrograde ejaculation; α-Blockade.
Similar articles
-
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Eur Urol. 2011. PMID: 21726934 Review.
-
[Prevalence of ejaculatory dysfunction secondary to alpha-blocker therapy in patients with benign prostatic hyperplasia].Actas Urol Esp. 2008 Jul-Aug;32(7):705-12. doi: 10.1016/s0210-4806(08)73918-4. Actas Urol Esp. 2008. PMID: 18788486 Spanish.
-
Patient-reported ejaculatory function and satisfaction in men with lower urinary tract symptoms/benign prostatic hyperplasia.Asian J Androl. 2018 Jan-Feb;20(1):69-74. doi: 10.4103/aja.aja_11_17. Asian J Androl. 2018. PMID: 28474611 Free PMC article.
-
Ejaculatory dysfunction in the treatment of lower urinary tract symptoms.Transl Androl Urol. 2016 Aug;5(4):450-9. doi: 10.21037/tau.2016.06.06. Transl Androl Urol. 2016. PMID: 27652217 Free PMC article. Review.
-
Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.BJU Int. 2009 Oct;104(7):974-83. doi: 10.1111/j.1464-410X.2009.08503.x. Epub 2009 May 7. BJU Int. 2009. PMID: 19426189
Cited by
-
Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.Drugs. 2011 May 7;71(7):897-907. doi: 10.2165/11204780-000000000-00000. Drugs. 2011. PMID: 21568366 Review.
-
Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.Cell Commun Signal. 2021 Jul 20;19(1):78. doi: 10.1186/s12964-021-00755-6. Cell Commun Signal. 2021. PMID: 34284799 Free PMC article. Review.
-
α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?Adv Ther. 2017 Jan;33(12):2110-2121. doi: 10.1007/s12325-016-0423-5. Epub 2016 Oct 17. Adv Ther. 2017. PMID: 27752927 Free PMC article. Review.
-
Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report.Drugs Aging. 2011 Oct 1;28(10):843-5. doi: 10.2165/11207800-000000000-00000. Drugs Aging. 2011. PMID: 21970311 No abstract available.
-
New Pimarane Diterpenoids Isolated from EtOAc-Extract of Apiospora arundinis Culture Medium Show Antibenign Prostatic Hyperplasia Potential.ACS Omega. 2024 Jan 22;9(5):5616-5623. doi: 10.1021/acsomega.3c07930. eCollection 2024 Feb 6. ACS Omega. 2024. PMID: 38343945 Free PMC article.
References
-
- Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1988;32:21–26. - PubMed
-
- Narayan P, Tewari A. Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology. 1998;51(suppl 1):38–45. - PubMed
-
- American Urological Association Education and Research, authors. Results of the Treatment Outcomes Analyses. 2006. [Accessed November 10, 2009]. pp. 1–142. (Guideline on the Management of Benign Prostatic Hyperplasia (BPH)). http://www.auanet.org/content/guidelines-and-quality-care/clinicalguidel....
-
- Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol. 1995;154:110–115. - PubMed
-
- Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007;4:368–378. - PubMed
LinkOut - more resources
Full Text Sources